Zepbound and Wegovy are both weekly injections for chronic weight management, but they are not the same drug and do not produce the same average results. Zepbound is tirzepatide, which acts on two gut hormone receptors. Wegovy is semaglutide, which acts on one. In a direct head-to-head trial, tirzepatide produced greater average weight loss. That average does not decide the right choice for any single person, because tolerability, coexisting conditions, coverage, and cost all matter as much as the headline number.
What is the mechanistic difference in zepbound vs wegovy?
Semaglutide is a GLP-1 receptor agonist. It mimics a hormone released after eating that slows stomach emptying, blunts appetite, and increases the sense of fullness. Tirzepatide does that and adds a second target: the GIP receptor. That dual action is the reason the two drugs behave differently in trials rather than a marketing distinction.
Both are given as a once-weekly subcutaneous injection with a slow dose escalation over several weeks. The escalation is not optional pacing; it is how the makers reduce nausea and gastrointestinal side effects early in treatment. The prescribing details for tirzepatide are laid out in the Zepbound label, and the same molecule under its diabetes brand appears in the Mounjaro label.
How much weight did each drug produce in trials?
The most useful evidence is a direct comparison. In a randomized trial published in the New England Journal of Medicine in 2024, adults with overweight or obesity were assigned to tirzepatide or semaglutide over 72 weeks. Tirzepatide produced a larger average reduction in body weight. This is the cleanest signal available that, on average, Zepbound outperforms Wegovy on the scale.
Each drug also has its own key trial. Tirzepatide was tested in SURMOUNT-1, where the highest dose produced mean weight reductions well above twenty percent in adults without diabetes. A separate trial, SURMOUNT-CN, tested tirzepatide in Chinese adults with obesity and showed meaningful reductions in that population too. These are separate studies, not a matchup, so they should be read as consistent evidence rather than a scoreboard.
Which route to a price applies to you?
| Route | What sets the number | Main limitation |
|---|---|---|
| Covered benefit | Formulary tier, deductible, coinsurance | Requires the plan to cover weight management |
| Manufacturer savings card | Commercial insurance status, eligibility rules | Usually excludes government insurance |
| Manufacturer self-pay | Fixed cash price set by the maker | Conditions on refill timing and dose |
| Compounded medication | Pharmacy and provider pricing | Not an FDA-approved product |
Do the side effects differ?
The side effect profiles overlap heavily. Both cause nausea, diarrhea, constipation, and vomiting most commonly, and both carry a boxed warning about thyroid C-cell tumors based on rodent studies. In practice the difference people report is one of degree and personal tolerance rather than category. Some tolerate one molecule far better than the other, which is a real reason to switch and a reason the more powerful drug on average is not automatically the right one for a given body.
There is one area where tirzepatide has evidence semaglutide does not. In a trial of adults with obstructive sleep apnea and obesity, tirzepatide reduced the severity of sleep apnea alongside weight loss. If a coexisting condition like that is in the picture, it can tip the decision more than a percentage point of weight difference.
What happens when treatment stops?
This is the part that gets skipped in the excitement over trial numbers, and it deserves plain attention. Both drugs were studied as ongoing therapy. In SURMOUNT-4, people who stopped tirzepatide after an initial lead-in regained a substantial share of the weight they had lost, while those who continued kept losing. The semaglutide equivalent, STEP 4, showed the same pattern of regain after withdrawal. Neither drug is a finite course. Anyone comparing them should assume the cost and the injection are indefinite, or plan deliberately for what happens if they stop.
How do the brands compare with older options?
It helps to know these are not the first drugs in the category. Semaglutide was compared with an earlier daily injection, liraglutide, in STEP 8, and produced clearly greater weight loss. The trend across a decade of trials is toward stronger effect sizes, with tirzepatide currently at the top of the approved options for average results. That trajectory is worth keeping in view, because the field keeps moving.
Where does cost and access fit?
Both brands list above a thousand dollars a month, and almost nobody pays that. Coverage is usually decided at the category level, so if a plan excludes weight management medication, both drugs are excluded together and a brand swap will not help. Manufacturer savings cards mostly assist people who already have commercial coverage, and both makers now run self-pay programs for cash payers.
Compounded semaglutide and tirzepatide sit outside all of that. They are prepared by compounding pharmacies and are not FDA-approved products, so they have not been through the process that generated the trial evidence above. What they often offer is a flat monthly cash price. Supervised telehealth practices such as formblends.com publish this kind of pricing with prescribing handled by a licensed clinician, and it is one legitimate option among named services like Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare. The honest framing is that a compounded route trades regulatory assurance for cost predictability, and that trade belongs with a prescriber who knows the case.
Key takeaways
- Tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy) in a direct 72-week trial.
- The average winner is not automatically the right fit; tolerability and coexisting conditions matter.
- Both drugs show substantial weight regain after stopping, so treatment is effectively ongoing.
- Compounded versions are not FDA-approved products and are a separate decision from the brands.
See also: Sports Car Rental Dubai – The Ultimate Experience of Power, Style, and Luxury
Frequently asked questions
Does Zepbound produce more weight loss than Wegovy?
On average, yes. A head-to-head trial published in 2024 found greater mean weight reduction with tirzepatide than with semaglutide over 72 weeks, but individual response varies widely and the more effective drug on paper is not always the better fit for a given person.
Are the two drugs the same class?
Not exactly. Wegovy is semaglutide, a GLP-1 receptor agonist. Zepbound is tirzepatide, which acts on both GIP and GLP-1 receptors. That second target is the main mechanistic difference between them.
Do I keep the weight off after stopping?
The trial data for both drugs shows substantial regain after treatment stops. Continuation studies for each treated the medication as ongoing therapy, not a finite course, which is a fact worth weighing before starting.
Is compounded tirzepatide or semaglutide the same as the brand?
No. Compounded versions are prepared by compounding pharmacies and are not FDA-approved products. They may use the same active molecule but have not gone through the approval process behind the brand trial evidence.
Which one should I ask for?
That depends on tolerability, coexisting conditions, coverage, and cost, not on the headline weight numbers alone. Both are approved for chronic weight management, and the right starting point is a prescriber who can weigh those factors.
